Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RPID
STRONG SELLRapid Micro Biosystems, Inc. · Healthcare · United States · $99M · Avg Vol: $450K/d
COMPANY DESCRIPTION
Rapid Micro Biosystems, Inc. develops and sells automated microbial detection systems, primarily for quality control applications within the pharmaceutical industry. Its flagship Growth Direct® System offers a significant competitive advantage by accelerating microbial enumeration and detection, reducing manual labor and time-to-result. This positions the company as a key innovator in pharmaceutical quality control and manufacturing efficiency.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.2M | 17.1M | 22.5M | 28.1M | 33.6M | 9.7% | 34.4M | 39.3M | 46.6M | 17.8% |
| EPS | -3.94 | -1.43 | -1.22 | -1.08 | -1.05 | — | -1.11 | -0.93 | -0.79 | — |
| Shares | 42.1M | 42.1M | 42.4M | 43.0M | 44.5M | +5.7% | 45.3M | — | — | — |
| Debt | 8.0M | 8.0M | 7.3M | 6.2M | 23.9M | 31.6% | 23.7M | — | — | — |
| Equity | 164.2M | 164.2M | 118.0M | 75.4M | 33.2M | -32.9% | — | — | — | — |
| Op CF | -55.0M | -58.5M | -45.1M | -44.2M | -31.1M | — | -37.1M | — | — | — |
| Inv CF | -13.3M | -93.5M | 42.2M | 36.7M | 14.3M | — | — | — | — | — |
| Fin CF | 216.7M | 0.7M | 0.1M | 0.2M | 19.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RPID are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RPID | Rapid Micro Biosystems, Inc.(you) | $99M | 4 | STRONG SELL |
| SERA | Sera Prognostics, Inc. | $80M | 5 | STRONG SELL |
| EBR.AX | EBR Systems, Inc. | $115M | 1 | STRONG SELL |
| LDX.AX | Lumos Diagnostics Holdings Limited | $75M | 3 | STRONG SELL |
| HYPR | Hyperfine, Inc. | $95M | 13 | STRONG SELL |
| CVRX | CVRx, Inc. | $126M | 12 | STRONG SELL |
| STIM | Neuronetics, Inc. | $120M | 15 | STRONG SELL |
| LNSR | LENSAR, Inc. | $69M | 11 | STRONG SELL |
| OWLT | Owlet, Inc. | $153M | 11 | STRONG SELL |
| LUCD | Lucid Diagnostics Inc. | $173M | 9 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%